Canaccord Genuity Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by analysts at Canaccord Genuity Group from $875.00 to $922.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group‘s price target indicates a potential upside of 13.37% from the company’s current price.

REGN has been the topic of a number of other research reports. HSBC increased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Finally, Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $847.90.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of Regeneron Pharmaceuticals stock traded down $2.83 during midday trading on Wednesday, reaching $813.27. The company had a trading volume of 535,599 shares, compared to its average volume of 812,805. The stock has a fifty day moving average price of $791.66 and a 200 day moving average price of $737.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $859.34. The firm has a market cap of $83.73 billion, a PE ratio of 20.10, a P/E/G ratio of 1.36 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Activity

In related news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 in the last three months. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $11,358,000. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $323,249,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.